BRNS

Company Overview: Barinthus Biotherapeutics is focusing on immunology and inflammatory diseases, with its lead candidate VTP-1000 for celiac disease currently in Phase 1 trials, and a proprietary SNAP-TI platform that promotes antigen-specific immune tolerance expected to drive future opportunities.

Financial Performance: The company reported a net loss of $61.1 million for 2024, down from $73.3 million in 2023, with cash reserves projected to fund operations into 2027, while also announcing strategic restructuring to prioritize immunological therapies.

Strategic Business Plans: Barinthus Biotherapeutics Plc. announced plans for cost savings, including potential closure of its UK site and layoffs affecting 65% of employees at two locations.

Financial Impact: The company anticipates these measures will extend its cash runway to early 2027, although its stock has decreased by 4.58% to $1.09 on the Nasdaq.

Leadership Change at Barinthus Biotherapeutics: Geoffrey Lynn, M.D., Ph.D. has been promoted to Chief Scientific Officer of Barinthus Bio, effective December 1, 2024, succeeding Nadège Pelletier, Ph.D., who is leaving for other opportunities after contributing significantly to the company's preclinical pipeline.

Company's Focus and Pipeline Development: Barinthus Bio is advancing immunotherapeutic candidates targeting chronic infectious diseases and autoimmunity, with notable products like VTP-300 for chronic hepatitis B and VTP-1000 for celiac disease currently in clinical trials.

Fastest News Alerts: Benzinga Pro offers real-time intelligence and news alerts to help traders stay informed and make winning trades in the stock market.

Community of Traders: The platform boasts a community of over 10,000 serious traders who benefit from exclusive stories and accurate market intelligence provided by Benzinga reporters.

Clinical Trial Results: Barinthus Biotherapeutics announced significant findings from their Phase 2b HBV003 clinical trial, revealing that eight participants achieved complete HBsAg loss and two met criteria for functional cure, indicating promising results for the immunotherapeutic candidate VTP-300 in combination with low-dose nivolumab.

Safety and Efficacy: The preliminary safety data showed that the treatment was well tolerated with no serious adverse events reported, suggesting that VTP-300 may effectively stimulate immune responses and lead to sustained reductions in HBsAg levels, potentially allowing chronic hepatitis B patients to discontinue antiviral treatments.

Clinical Trial Results: Preliminary data from the Phase 2a IM-PROVE II clinical trial show that participants receiving a combination of imdusiran, VTP-300, and low-dose nivolumab experienced significantly greater declines in HBsAg levels, with 23% achieving HBsAg loss by Week 48.

Therapeutic Approach: The combination treatment is believed to enhance immune response against chronic hepatitis B virus infection, demonstrating promising results without significant adverse effects, supporting further development of these therapeutic candidates.

Real-time Intelligence: Benzinga Pro offers traders the fastest and most accurate stock market intelligence, helping them make informed decisions daily.

Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from exclusive stories and alerts generated by Benzinga reporters.

Clinical Presentation Announcement: Barinthus Biotherapeutics will present updated clinical data on its chronic hepatitis B program at the AASLD – The Liver Meeting® 2024, highlighting a late-breaking abstract regarding VTP-300 and its effects in patients with low HBsAg levels.

Company Overview and Future Plans: Barinthus Bio focuses on developing immunotherapeutic candidates for chronic infectious diseases and autoimmunity, with ongoing trials for products like VTP-300 and VTP-1000, while also participating in various medical and investor conferences throughout November 2024.

Clinical Trials Update: Barinthus Biotherapeutics has completed enrollment for two clinical trials: HBV003, a Phase 2b trial of VTP-300 for chronic hepatitis B, and PCA001, a Phase 1 trial of VTP-850 for recurrent prostate cancer, with data updates expected in late 2024 and early 2025 respectively.

Immunotherapy Development: The trials aim to evaluate the safety and efficacy of novel immunotherapeutic candidates, with VTP-300 showing promise in reducing Hepatitis B surface antigen levels and VTP-850 targeting rising PSA levels in prostate cancer patients.

Fastest News Alerts: Benzinga Pro offers real-time intelligence and news alerts to help traders stay informed and make winning trades in the stock market.

Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.

Investigational Immunotherapy: Barinthus Biotherapeutics has initiated a Phase 1 trial for VTP-1000, an immunotherapy aimed at treating celiac disease, which currently has no approved treatments. The trial will assess the safety and tolerability of the drug in adults with celiac disease.

Celiac Disease Overview: Celiac disease affects approximately one in 100 people globally, causing severe autoimmune reactions to gluten, leading to gastrointestinal symptoms and long-term health issues. The investigational therapy aims to restore immune tolerance to gluten, potentially improving the quality of life for those affected.

Board Appointments: Sagimet Biosciences has appointed Anne Phillips and Jennifer Jarrett to its board of directors as the company prepares to initiate Phase 3 clinical development of its drug denifanstat for treating metabolic dysfunction-associated steatotic liver disease (MASH).

Expertise and Impact: Both appointees bring extensive experience in the biopharmaceutical industry, with Phillips focusing on regulatory affairs and clinical development, while Jarrett contributes expertise in finance and corporate operations, crucial for advancing Sagimet's therapeutic pipeline.

• Spectaire Holdings Inc rose by 110%.
• DermTech, Inc. gained 105.5% after filing for Chapter 11 protection.
• Trinity Place Holdings Inc. shares rose by 35.7%.
• Barinthus Biotherapeutics PLC – ADR shares increased by 25.5%.
• Zoomcar Holdings, Inc. rose by 22.5%.

• Psyence Biomedical Ltd. fell by 23.6%.
• Professional Diversity Network, Inc. dropped by 21.1%.
• SMX (Security Matters) Public Limited Company shares declined by 18.5%.
• Ensysce Biosciences, Inc. fell by 17.6%.
• Reliance Global Group, Inc. shares decreased by 16.8%.